Home/Enliven Therapeutics/Joe Lyssikatos
JL

Joe Lyssikatos

Co-founder and Chief Scientific Officer

Enliven Therapeutics

Therapeutic Areas

Enliven Therapeutics Pipeline

DrugIndicationPhase
ELVN-001Chronic Myeloid Leukemia (CML)Phase 1b